Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Income from Continuing Operations of 23385000.0 for Q2 2026, down 7.16% year-over-year from 25189173.7 in Q2 2025, and down 11.4% on a QoQ basis from 20992000.0 in Q1 2026.
Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 23385000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 23385000.0, down 7.16% year-over-year; the trailing twelve-month figure through Jun 2026 was 81825000.0 (down 11.06% YoY), and the FY2025 annual result was 53792539000.0, down 173.08% from the prior year.
- Income from Continuing Operations slipped to 23385000.0 in Q2 2026, from 20992000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 13299000.0 in Q1 2024 and troughed at 10552338000.0 in Q4 2022.
- A 5-year average of 606767055.56 and a median of 21225500.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2022, when Income from Continuing Operations slumped 92733.1%; it then soared 99.54% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 10552338000.0 in 2022, then soared by 99.54% to 48302000.0 in 2023, then jumped by 66.28% to 16288000.0 in 2024, then fell by 11.63% to 18183000.0 in 2025, then dropped by 28.61% to 23385000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 23385000.0 in Q2 2026, 20992000.0 in Q1 2026, and 18183000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | -23.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.39 Mn |
| Mar 31, 2026 | -20.99 Mn |
| Dec 31, 2025 | -18.18 Mn |
| Sep 30, 2025 | -19.27 Mn |
| Jun 30, 2025 | -21.82 Mn |
| Mar 31, 2025 | -20.26 Mn |
| Dec 31, 2024 | -16.29 Mn |
| Sep 30, 2024 | -15.31 Mn |
| Jun 30, 2024 | -14.00 Mn |
| Mar 31, 2024 | -13.30 Mn |
| Dec 31, 2023 | -48.30 Mn |
| Sep 30, 2023 | -19.39 Mn |
| Jun 30, 2023 | -24.62 Mn |
| Mar 31, 2023 | -24.45 Mn |
| Dec 31, 2022 | -20.41 Mn |
| Sep 30, 2022 | -24.60 Mn |
| Jun 30, 2022 | -21.46 Mn |
| Mar 31, 2022 | -15.77 Mn |
| Dec 31, 2021 | -11.37 Mn |
| Sep 30, 2021 | -15.96 Mn |